Trillium Therapeutics Inc. (NASDAQ:TRIL) went down by -0.84% from its latest closing price compared to the recent 1-year high of $20.96. The company’s stock price has collected 0.11% of gains in the last five trading sessions. Press Release reported on 09/21/21 that SHAREHOLDER ALERT: WeissLaw LLP Reminds DSPG, ADTN, TRIL, and VNE Shareholders About Its Ongoing Investigations
Is It Worth Investing in Trillium Therapeutics Inc. (NASDAQ :TRIL) Right Now?
Trillium Therapeutics Inc. (NASDAQ:TRIL) scored a price-to-earnings ratio above its average ratio, recording 72.11 x from its present earnings ratio. Plus, the 36-month beta value for TRIL is at 1.98. Opinions of the stock are interesting as 2 analysts out of 7 who provided ratings for Trillium Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $18.50, which is -$6.74 below the current price. TRIL currently public float of 98.89M and currently shorts hold a 10.01% ratio of that float. Today, the average trading volume of TRIL was 2.74M shares.
TRIL’s Market Performance
TRIL stocks went up by 0.11% for the week, with a monthly jump of 3.26% and a quarterly performance of 126.82%, while its annual performance rate touched 16.31%. The volatility ratio for the week stands at 1.13% while the volatility levels for the past 30 days are set at 1.11% for Trillium Therapeutics Inc.. The simple moving average for the period of the last 20 days is 1.04% for TRIL stocks with a simple moving average of 55.36% for the last 200 days.
Analysts’ Opinion of TRIL
Many brokerage firms have already submitted their reports for TRIL stocks, with The Benchmark Company repeating the rating for TRIL by listing it as a “Buy.” The predicted price for TRIL in the upcoming period, according to The Benchmark Company is $21 based on the research report published on April 14th of the current year 2021.
H.C. Wainwright gave a rating of “Buy” to TRIL, setting the target price at $16.50 in the report published on September 10th of the previous year.
TRIL Trading at 25.63% from the 50-Day Moving Average
After a stumble in the market that brought TRIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.27% of loss for the given period.
Volatility was left at 1.11%, however, over the last 30 days, the volatility rate increased by 1.13%, as shares surge +2.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +176.64% upper at present.
During the last 5 trading sessions, TRIL rose by +0.11%, which changed the moving average for the period of 200-days by +36.41% in comparison to the 20-day moving average, which settled at $17.60. In addition, Trillium Therapeutics Inc. saw 20.73% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at TRIL starting from Uger Robert, who sale 3,646 shares at the price of $9.00 back on Jul 07. After this action, Uger Robert now owns 0 shares of Trillium Therapeutics Inc., valued at $32,814 using the latest closing price.
Uger Robert, the Chief Scientific Officer of Trillium Therapeutics Inc., sale 3,646 shares at $8.27 during a trade that took place back on Jun 07, which means that Uger Robert is holding 0 shares at $30,152 based on the most recent closing price.
Stock Fundamentals for TRIL
Current profitability levels for the company are sitting at:
- -33077.70 for the present operating margin
The net margin for Trillium Therapeutics Inc. stands at -40098.65. The total capital return value is set at -36.74, while invested capital returns managed to touch -44.62. Equity return is now at value -19.20, with -16.90 for asset returns.
Based on Trillium Therapeutics Inc. (TRIL), the company’s capital structure generated 0.30 points at debt to equity in total, while total debt to capital is 0.30. Total debt to assets is 0.28, with long-term debt to equity ratio resting at 0.21. Finally, the long-term debt to capital ratio is 0.20.
When we switch over and look at the enterprise to sales, we see a ratio of 6,219.74, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 0.24 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.94.